ArticleFrontiers in bioengineering and biotechnology2026
Collagen targeted self-anchoring antimicrobial molecular agents.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The intrinsic characteristics of collagen, when combined with its natural abundance in the tissues and its easy exposure due to any fissure of epithelium during a wound or an injury, makes it a common site for bacterial colonization. Within dense collagen fibrils, such as those in dentin, bound pathogens are partially shielded from antibiotic penetration. With the increasing prevalence of antibiotic resistance, microbial infections remain a persistent global health concern. In this study, we engineered a collagen targeted self-anchoring antimicrobial peptide as a novel therapeutic agent and tested its multifunctional activities on a collagen platform. Our peptide design incorporated an antimicrobial peptide (AMP) with another peptide designed for collagen-binding properties through a spacer domain. The novel collagen targeted AMP (COLTAMP) peptide was computationally evaluated for its potential to simultaneously exhibit both desired functions, collagen-binding and antibacterial activity. The predicted secondary structure of COLTAMP was confirmed using Fourier-transform infrared and Raman spectroscopies as complementary vibrational techniques. The interactions of the targeted AMP with collagen fibrils were characterized using atomic force microscopy, providing insights into the effects of the peptide on the organization of fibrils. The antimicrobial activity of the targeted AMP was tested using a zone of inhibition assay against a model pathogen,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.